share_log

Transcode Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Thomas A. Fitzgerald(5.5%)

Transcode Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Thomas A. Fitzgerald(5.5%)

Transcode Therapeutics | SC 13D:超過5%持股股東披露文件-Thomas A. Fitzgerald(5.5%)
美股SEC公告 ·  06/21 16:09

Moomoo AI 已提取核心訊息

Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.
Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.
TransCode Therapeutics公司的代理CEO、CFO和董事之一Thomas A. Fitzgerald於2024年6月21日向SEC提交了13D日程表,表明他在該公司擁有重要的所有權。Fitzgerald報告了422,036股TransCode Therapeutics普通股,這相當於該公司流通股的約5.5%。這一股份包括直接持有的1,408股和在提交日期後60天內行權的期權可行權的420,628股。提交的文件中詳細說明了Fitzgerald對公司活動的潛在影響,還指出他在未來有權獲得額外的股份或處置他的持股。預計Fitzgerald的投資決策將受到各種因素的影響,包括公司的業務前景和市場條件。
TransCode Therapeutics公司的代理CEO、CFO和董事之一Thomas A. Fitzgerald於2024年6月21日向SEC提交了13D日程表,表明他在該公司擁有重要的所有權。Fitzgerald報告了422,036股TransCode Therapeutics普通股,這相當於該公司流通股的約5.5%。這一股份包括直接持有的1,408股和在提交日期後60天內行權的期權可行權的420,628股。提交的文件中詳細說明了Fitzgerald對公司活動的潛在影響,還指出他在未來有權獲得額外的股份或處置他的持股。預計Fitzgerald的投資決策將受到各種因素的影響,包括公司的業務前景和市場條件。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息